Suppr超能文献

无免疫抑制的IgA肾病患者毛细血管内细胞增多的预后价值

Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

作者信息

Chakera Aron, MacEwen Clare, Bellur Shubha S, Chompuk La-Or, Lunn Daniel, Roberts Ian S D

机构信息

School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

Oxford Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, UK.

出版信息

J Nephrol. 2016 Jun;29(3):367-375. doi: 10.1007/s40620-015-0227-8. Epub 2015 Aug 30.

Abstract

AIM

Interpretation of retrospective clinicopathological studies of IgA nephropathy (IgAN) has been confounded by immunosuppression bias. In published validation studies of the Oxford Classification of IgAN, an average of 33 % of patients received non-randomised steroid and/or cytotoxic therapy. In order to determine the true impact of proliferative lesions on the natural history of IgAN, analysis of patient cohorts that have received no immunosuppression is required.

METHODS

We performed a retrospective single centre study of patients with IgAN managed without immunosuppressive therapy. Biopsies were scored according to the Oxford Classification. The primary outcomes were renal survival or a rapid loss of renal function defined as a decline in eGFR of >5 ml/min/year.

RESULTS

237 patients with IgAN were identified with a mean follow-up of 82 months. 200 had biopsies available for review, of which 156 were adequate for scoring using the Oxford Classification. 9/156 patients (5.8 %) received some immunosuppressive therapy, mostly for unrelated conditions: these were excluded. In multivariate COX regression, including histological and clinical data, the only independent predictors of time to ESRD were baseline eGFR (HR 0.96 per ml/min increase, p = 0.018), baseline proteinuria (HR 1.36 per doubling, p = 0.004) and endocapillary hypercellularity (HR 4.75 for E1 compared to E0, p < 0.001). Independent predictors of a rapid decline in eGFR were proteinuria (OR 1.45 per doubling, p = 0.006), endocapillary hypercellularity (OR 3.41 for E1 compared to E0, p = 0.025) and tubular atrophy/interstitial fibrosis (OR 8.77 for T2 compared to T0, p = 0.006).

CONCLUSIONS

In a cohort of IgAN patients receiving no immunosuppression, endocapillary proliferation and tubular atrophy/interstitial fibrosis are independent predictors of rate of loss of renal function. The lack of predictive value of E score in other clinicopathological studies is most likely a result of immunosuppression-associated bias. Our findings provide evidence to support immunosuppressive treatment of endocapillary-pattern IgAN.

摘要

目的

免疫抑制偏倚一直困扰着IgA肾病(IgAN)回顾性临床病理研究的解读。在已发表的IgAN牛津分类法验证研究中,平均33%的患者接受了非随机的类固醇和/或细胞毒性治疗。为了确定增殖性病变对IgAN自然病程的真正影响,需要分析未接受免疫抑制治疗的患者队列。

方法

我们对未接受免疫抑制治疗的IgAN患者进行了一项回顾性单中心研究。活检标本根据牛津分类法进行评分。主要结局是肾脏存活情况或肾功能快速丧失,定义为估算肾小球滤过率(eGFR)下降>5 ml/min/年。

结果

共纳入237例IgAN患者,平均随访82个月。其中200例有活检标本可供复查,156例标本适合用牛津分类法评分。156例患者中有9例(5.8%)接受过某种免疫抑制治疗,主要用于治疗无关疾病,这些患者被排除。在多因素COX回归分析中,纳入组织学和临床数据,终末期肾病(ESRD)发生时间的唯一独立预测因素是基线eGFR(每增加1 ml/min,风险比[HR]为0.96,p = 0.018)、基线蛋白尿(每增加一倍,HR为1.36,p = 0.004)和内皮细胞增生(E1期与E0期相比,HR为4.75,p < 0.001)。eGFR快速下降的独立预测因素是蛋白尿(每增加一倍,比值比[OR]为1.45,p = 0.006)、内皮细胞增生(E1期与E0期相比,OR为3.41,p = 0.025)和肾小管萎缩/间质纤维化(T2期与T0期相比,OR为8.77,p = 0.006)。

结论

在未接受免疫抑制治疗的IgAN患者队列中,内皮细胞增生和肾小管萎缩/间质纤维化是肾功能丧失率的独立预测因素。在其他临床病理研究中E评分缺乏预测价值很可能是免疫抑制相关偏倚导致的结果。我们的研究结果为支持对内皮细胞型IgAN进行免疫抑制治疗提供了证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验